Amgen (AMGN) Announces Positive Results for Phase 3 Study of Bemarituzumab

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 30, Amgen Inc. (NASDAQ:AMGN) announced positive topline results for an important phase 3 study of Bemarituzumab for certain stomach cancers.

The company announced that the Phase 3 FORTITUDE-101 trial met its primary endpoint. The Bemarituzumab plus chemotherapy significantly improved overall survival in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer with FGFR2b overexpression and who are non-HER2 positive.

Amgen (AMGN) Announces Positive Results for Phase 3 Study of Bemarituzumab

A pharmacist filling a prescription for a complex drug developed by the company.

Gastric cancer is the fifth leading cause of cancer-related death globally, with nearly 1 million new cases and over 650,000 deaths each year. Bemarituzumab is a first-in-class, Fc-optimized monoclonal antibody that targets FGFR2b, a protein overexpressed in a subset of gastric cancers. Management noted that detailed results will be presented in future meetings, and a separate Phase 3 trial of Bemarituzumab plus chemotherapy and nivolumab is ongoing, with results expected in the second half of 2025.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that develops innovative medicines for serious diseases with limited treatments.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.